NURS 504 Week 8 ADHD Case Study Analysis Example

ADHD Case Study Analysis: Starting a Long-Acting Stimulant, With Parent Training and a School Plan, for an Eight-Year-Old Third Grader

Case Summary

The patient is an eight-year-old in third grade brought in by a parent after the teacher reported that the child rarely finishes classwork, calls out answers, leaves the seat often and loses materials daily. At home, homework takes two hours of reminders and the child interrupts conversations constantly. These behaviors have been present since kindergarten. Vanderbilt rating scales completed by the parent and the teacher both show six or more inattentive and six or more hyperactive-impulsive symptoms with impairment in schoolwork and peer relationships. The child sleeps about nine hours, eats well, takes no medications and has had normal growth. There is no history of fainting, chest pain, palpitations, heart disease or seizures, and no family history of sudden or unexplained death in a young person. Blood pressure and heart rate are normal for age. Screening questions for anxiety, depression, learning disorders and tics are negative, though reading is slightly below grade level.

Assessment

The child meets criteria for attention-deficit/hyperactivity disorder, combined presentation, with symptoms documented by both parent and teacher in two settings, present before age 12 and causing impairment. The slightly low reading level should be watched; if it persists after attention improves, testing for a learning disability is appropriate, since coexisting conditions are common. For an eight-year-old, the question is not medication or behavior therapy but how to combine them well.

Treatment Plan

The Guideline's Combined Approach

For children aged 6 to 11, the American Academy of Pediatrics pairs an FDA-approved medicine with two behavioral supports, a parent course in managing behavior and classroom strategies, with educational supports such as an individualized education program or a Section 504 plan as part of any plan (Wolraich et al., 2019). Evidence supports both components. Across 14 months and 579 children in the MTA trial, a tightly supervised medication strategy outperformed for core ADHD symptoms than intensive behavioral treatment alone, while combined treatment offered advantages for some outcomes such as family relationships and fewer medication doses needed (MTA Cooperative Group, 1999).

Medication: Extended-Release Methylphenidate

The recommended medication is an extended-release methylphenidate, for example an osmotic-release formulation starting at 18 mg each morning. Methylphenidate blocks reuptake of dopamine and norepinephrine in the prefrontal cortex and striatum, strengthening the signals that support attention and inhibition (Burchum & Rosenthal, 2019). When a large network meta-analysis weighed benefit against side effects across many trials, methylphenidate came out as the best first choice for young people under 18 (Cortese et al., 2018). An extended-release form lasts through the school day so no dose is needed at school, which avoids stigma and the logistics of a school dose.

Titration

The dose should be increased weekly, for example to 27 mg and then 36 mg, until symptoms are well controlled or side effects limit further increases, using parent and teacher rating scales each week to judge response. Most children reach their best dose within a month, and the right dose is the one that controls symptoms in both settings with tolerable side effects, not a dose chosen by weight. If methylphenidate is not tolerated or not effective at adequate doses, an amphetamine product is a reasonable next step, and a nonstimulant such as extended-release guanfacine or atomoxetine is an option when stimulants cannot be used (Wells et al., 2018). Atomoxetine carries a boxed warning about suicidal thinking in children and adolescents and requires monitoring.

Parent Training and School Plan

The parents should be referred to an evidence-based parent training program in behavior management, which teaches consistent routines, praise for desired behavior and planned consequences. The family should request a Section 504 plan from the school, with supports such as preferential seating, broken-down assignments, a daily report card shared between teacher and parents, and extra time for tests. The daily report card also gives the clinician weekly data on response to treatment.

Coordinating Home, School and Clinic

A plan with three parts needs one person keeping them connected. The nurse can serve that role by sending the school a brief letter, with the parents' consent, describing the diagnosis, the medication timing and the rating scales the clinic would like the teacher to complete weekly during titration. The parents bring the completed scales and the daily report cards to each visit or upload them to the portal, and the nurse reviews them before the clinician's call so the dose decision rests on data from both settings. When the parent training program ends, the nurse can ask which strategies the family is still using, since those habits fade without reinforcement. This coordination is often the difference between a treatment that works on paper and one that works in the classroom.

Pre-Treatment Safety Questions

The cardiac history questions were asked and were negative, so no electrocardiogram or cardiology referral is needed before starting a stimulant (Wolraich et al., 2019). Baseline height, weight, blood pressure and heart rate have been recorded for comparison, along with the child's usual bedtime and appetite.

Monitoring and Adverse Effects

Common stimulant side effects include decreased appetite, trouble falling asleep, stomachaches, headaches, and a cranky late afternoon when the medicine's effect fades. Appetite effects can be eased by giving the dose with breakfast and offering a larger evening snack. Blood pressure and heart rate rise modestly and should be checked at each visit. Height and weight should be plotted on growth charts at each visit, since stimulants can slow growth slightly. Rarely, stimulants can worsen tics or cause mood changes or hallucinations, which require a call (Burchum & Rosenthal, 2019). Follow-up should occur weekly by phone or portal during titration, at one month in person and every three months once stable.

Controlled-Substance Safety

Methylphenidate is a Schedule II controlled substance. The family should store it in a locked location, count the tablets, give it only to the child, never share it and dispose of unused tablets at a take-back site. Prescriptions cannot be refilled and must be renewed, which should be planned so the child does not run out over weekends or holidays. Older siblings and visiting friends are a known source of diversion, so the locked storage applies even in households where misuse seems unlikely.

Family Education

The parents should understand that ADHD is a neurodevelopmental condition, not a result of poor parenting or a lack of effort, that medication improves attention and self-control while it is active but does not cure the condition, and that behavioral strategies build skills that last. They should know which effects to report and expect the dose to change more than once in the first month. The child, at an age-appropriate level, can be told that the medicine helps the brain focus so it is easier to finish work and get along with friends.

Teaching Points for Nursing Students

This case teaches three lessons for students. First, ADHD treatment in school-age children combines medication with behavioral and school supports, and nurses can coordinate these across home and school. Second, stimulant dosing is titrated to response, and rating scales give that response a number. Third, controlled-substance safety, storage, counting and disposal, is part of every stimulant prescription and is a teaching task nurses are well placed to carry out.

References

Burchum, J. R., & Rosenthal, L. D. (2019). Lehne's pharmacology for nursing care (10th ed.). Elsevier.

Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., Hollis, C., Simonoff, E., Zuddas, A., Barbui, C., Purgato, M., Steinhausen, H. C., Shokraneh, F., Xia, J., & Cipriani, A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727-738. https://doi.org/10.1016/S2215-0366(18)30269-4

MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56(12), 1073-1086. https://doi.org/10.1001/archpsyc.56.12.1073

Wells, B. G., DiPiro, J. T., Schwinghammer, T. L., & DiPiro, C. V. (2018). Pharmacotherapy handbook (10th ed.). McGraw-Hill Education.

Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., Holbrook, J. R., Lehmann, C. U., Lessin, H. R., Okechukwu, K., Pierce, K. L., Winner, J. D., & Zurhellen, W. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), Article e20192528. https://doi.org/10.1542/peds.2019-2528